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Abstract 23 
 24 
Lipopolysaccharide (LPS), the endotoxin of gram-negative bacteria, has detrimental effects 25 
on structure and function of the bovine corpus luteum (CL) in vivo. The objective was to 26 
investigate whether these effects were mediated directly by LPS or via LPS-induced release of 27 
PGF2α. Bovine ovaries with a mid-cycle CL were collected immediately after slaughter and 28 
isolated perfused for 240 min. After 60 min of equilibration, LPS (0.5 µg/mL) was added to 29 
the medium of five ovaries, whereas an additional six ovaries were not treated with LPS 30 
(control). After 210 min of perfusion, all ovaries were treated with 500 iu of hCG. In the 31 
effluent perfusate, concentrations of progesterone (P4) and PGF2α were measured every 10 32 
and 30 min, respectively. Punch biopsies of the CL were collected every 60 min and used for 33 
RT-qPCR to evaluate mRNA expression of receptors for LPS (TLR2, -4) and LH (LHCGR), 34 
the cytokine TNFA, steroidogenic (STAR, HSD3B), angiogenic (VEGFA121, FGF2) and 35 
vasoactive (EDN1) factors, and factors of prostaglandin synthesis (PGES, PGFS, PTGFR) 36 
and apoptosis (CASP3, -8, -9). Treatment with LPS abolished the hCG-induced increase in P4 37 
(P≤0.05); however, there was only a tendency (P=0.10) for increased release of PGF2α at 38 
70 min after LPS challenge. Furthermore, mRNA abundance of TLR2, TNFA, CASP3, 39 
CASP8, PGES, PGFS, and VEGFA121 increased (P≤0.05) after LPS treatment, whereas all 40 
other factors remained unchanged (P>0.05). In conclusion, reduced P4 responsiveness to hCG 41 
in LPS-treated ovaries in vitro was not due to reduced steroidogenesis, but was attributed to 42 
enhanced apoptosis. However, an impact of luteal PGF2α could not be excluded. 43 
 44 
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1. Introduction 47 
 48 
Fertility in dairy cows has decreased for more than a half century (Walsh et al. 2011), 49 
due in part to inflammatory diseases (Barker et al. 1998, LeBlanc et al. 2002). Cows with 50 
endometritis have prolonged calving-to-conception intervals (CCI) and are replaced sooner, 51 
due to reproductive failure (LeBlanc et al. 2002). Furthermore, inflammation in non-genital 52 
tissues (e.g. mastitis) also prolonged CCI and increased the number of services per conception 53 
(Barker et al. 1998), attributed in part to activation of immune cells by bacterial cell wall 54 
components and production of cytokines (Hansen et al. 2004). 55 
In previous studies (Suzuki et al. 2001, Herzog et al. 2012), lipopolysaccharide (LPS), 56 
the endotoxin from the outer membrane of gram-negative bacteria, was used as a model to 57 
determine effects of inflammation on fertility in cows. Binding of LPS to toll-like receptor 58 
(TLR) 4 (Akira 2003) activates macrophages and triggers cytokine production. Furthermore, 59 
instillation of LPS in the mammary gland consistently increases systemic concentrations of 60 
cytokine tumor necrosis factor alpha (TNFA; Blum et al. 2000). In addition, exogenous LPS 61 
reduced fertility due to impairment of ovarian follicular development and ovulation (Suzuki et 62 
al. 2001, Lavon et al. 2008, Williams et al. 2008). In cows given LPS during proestrus, the 63 
LH peak was significantly retarded or completely inhibited (Suzuki et al. 2001). Furthermore, 64 
LPS affected morphology and function of the bovine CL. In that regard, intravenous LPS 65 
decreased blood progesterone (P4) concentrations (Giri et al. 1991, Herzog et al. 2012) and 66 
caused temporary reductions in both luteal size and blood flow (Herzog et al. 2012). Since 67 
PGF2α metabolite concentrations were increased after LPS treatment (Herzog et al. 2012), 68 
which was consistent with increased PGF2α release from the endometrium during 69 
inflammation (Giri et al. 1991, Miyamoto et al. 2000, Skarzynski et al. 2000), it was 70 
speculated that enhanced uterine PGF2α induced premature luteolysis. It was noteworthy that 71 
TNFA consistently stimulated PGF2α synthesis in endometrial cells during all stages of the 72 
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estrous cycle (Miyamoto et al. 2000). However, a more recent study (Mishra & Dhali 2007) 73 
suggested that LPS might impair the CL, independent of endometrium-derived PGF2α. In that 74 
study, which used a luteal monolayer culture, LPS induced oxidative stress and decreased cell 75 
viability, although an influence of endometrium-derived PGF2α was excluded. 76 
In ruminants, the in vitro model of an isolated perfused ovary (IPO) was introduced 77 
several decades ago (Romanoff & Pincus 1962, Mills & Morrissette 1970, Stahler & Huch 78 
1971, Sturm & Stahler 1971, Janson et al. 1978), mainly to investigate ovarian steroid 79 
biosynthesis and energy metabolism. For studying mechanisms of LPS action on the bovine 80 
CL, with special consideration of the impact of uterine-derived PGF2α, this model has 81 
important advantages. At first, compared to in vivo studies, the IPO model facilitates 82 
determining LPS effects on the CL, excluding any influence of PGF2α from extra-luteal 83 
sources. Therefore, this model should be a good alternative to LPS, which has severe systemic 84 
effects on cows (Giri et al. 1990, Giri et al. 1991, Herzog et al. 2012). Secondly, compared to 85 
cell cultures, the IPO model enables interactions between various cell types (e.g. luteal, 86 
vascular, and stromal cells) of the bovine CL without changing their composition and 87 
arrangement, including an intact three-dimensional structure and intercellular communication 88 
(Brannstrom & Flaherty 1995). Furthermore, the structural integrity of the CL within the 89 
surrounding ovarian tissue was maintained in IPO (Stahler & Huch 1971) compared to tissue 90 
culture systems. 91 
Using the IPO technique, determination of P4 and PGF2α in the effluent perfusate 92 
enables direct assessment of release of these hormones from the CL. Progesterone synthesis is 93 
the most important indicator of functional integrity of the CL (Rekawiecki et al. 2008). In that 94 
regard, increased P4 synthesis following LH treatment is evidence of CL responsiveness 95 
(Skarzynski et al. 2008). Prostaglandin F2α is the most effective mediator of luteolysis in 96 
ruminants (McCracken et al. 1999). During physiologic luteolysis in cattle, PGF2α is released 97 
from the endometrium as well as the CL (Shirasuna et al. 2004). Furthermore, gene 98 
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expression of steroidogenic, angiogenic and vasoactive factors in luteal tissue provided 99 
relevant information regarding functionality of the bovine CL (Miyamoto et al. 2009, 100 
Shirasuna et al. 2010). The proinflammatory cytokine TNFA is present in bovine luteal cells, 101 
as well as in immune cells (mainly macrophages; Sakumoto et al. 2011), and is capable of 102 
reducing P4 secretion, increasing PGF2α production and inducing apoptosis in luteal cell 103 
cultures (Okuda & Sakumoto 2003, Skarzynski et al. 2005). 104 
In this study, we hypothesized that LPS directly suppresses CL function via enhanced 105 
apoptosis. Thus, the isolated perfused ovary model was established, and the impact of LPS 106 
challenge using this in vitro system was evaluated in detail. 107 
108 
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2. Materials and Methods 109 
 110 
2.1. Ovaries 111 
 112 
Ovaries with mesovarium were harvested from the carcasses of clinically healthy cows 113 
(Bos taurus; including Holstein Friesian, Red Holstein, Swiss Fleckvieh and Brown Swiss) 114 
that were slaughtered at a commercial abattoir. Sixteen ovaries containing a CL with an 115 
estimated diameter of >20 mm (subsequently confirmed as a mid-cycle CL) and intact tunica 116 
albuginea as well as mesovarium with ovarian vessels were used. 117 
 118 
2.2. Preparation of ovaries 119 
 120 
Immediately after the ovary was recovered, the ramus uterinus and all branches of the 121 
ovarian artery with a similar diameter were ligated (Polysorb 0®; Corvidien, Dublin, Ireland). 122 
Since the ovarian artery splits into small vessels and forms a convolute that surrounds the 123 
ovarian vein before entering the ovary, catheterization was performed proximal to the location 124 
where the ramus uterinus branches from the ovarian artery (Fig. 1). The ovarian artery was 125 
bluntly dissected from the connective tissue, stretched, cut diagonally and enlarged by 126 
catheterization with peripheral venous catheters (Terumo Surflow®; Terumo Europe, Leuven, 127 
Belgium) using increasing diameters (20 and 18 gauge) until a permanent 16 gauge venous 128 
catheter (Vygonüle T; Vygon, Écouen, France) could be installed. The catheter was fixed 129 
within the ovarian artery with two circular ligatures (Polysorb 0®). 130 
To avoid coagulation of blood within the vessels, ovaries were flushed with chilled 131 
(4 °C), heparinized (Heparin Bichsel 5000 IE/ml®; Bichsel AG, Interlaken, Switzerland; 132 
150 iu heparin/mL medium) Tyrode’s solution, containing 136 mmol/L NaCL, 11.9 mmol/L 133 
NaHCO3, 5.5 mmol/L D(+)glucose * H2O, 2 mmol/L KCL, 1.8 mmol/L CaCL2 * 2H2O, 134 
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1.05 mmol/L MgCL2 * 6H2O, 0.416 mmol/L NaH2PO4, and 6% (w/v) dextran 70 000 added 135 
to distilled water to a volume of 1 L. Flushing was continued until the effluent perfusate was 136 
macroscopically clear and the color of the CL changed from red to yellow. Flushed ovaries 137 
were transported to the laboratory in ice-chilled heparinized Tyrode’s solution. 138 
In the laboratory, ovaries with a vascular pedicle were weighed with a precision balance 139 
(Mettler PM 400®; Mettler-Toledo, Greifensee, Switzerland), and average diameter of the CL 140 
was determined with ultrasonography (Aquila Esaote Pie Medical; Esaote Biomedica, 141 
Cologne, Germany). Only ovaries with a luteal diameter >20 mm were used. Ovaries were 142 
fixed with two sutures (Polysorb 0®) at their extremitas tubaria and uterina on a bipod 143 
(Fig. 2). Gravity induced the margo liber of the ovary to point upwards and the margo 144 
mesovaricus to point downwards, with the free ends of the ovarian artery (catheterized) and 145 
vein (without catheter) positioned directly above a funnel. 146 
 147 
2.3. Isolated perfusion of ovaries 148 
 149 
Ovaries (fixed on the bipod) were put in an incubator for newborn humans (Atom Infant 150 
Incubator V-850; Atom Medical Corporation, Tokyo, Japan) to ensure perfusion under 151 
standardized microclimatic conditions (temperature, 37.5 to 38.5 °C; relative humidity, 75 to 152 
85%). A schematic illustration of the complete set-up is shown (Figure 3). 153 
As medium for the isolated perfusion of the ovary, a modified Tyrode’s solution was 154 
used (for detailed composition see Section 2.2.). Osmotically active dextran 70 000 was added 155 
to the original formula of Tyrode’s solution to reduce intercellular edema in the ovary, as 156 
suggested (Janson et al. 1978, Bjersing et al. 1981). Tyrode’s solution was oxygenated with 157 
carbogen (Oxycarbon medizinal; PanGas, Dagmersellen, Switzerland) using a hollow fiber 158 
type oxygenator (Membrana Oxyphan PP50/200; Membrana GmbH, Wuppertal, Germany). 159 
To ensure adequate oxygenation, pH and partial pressures of oxygen and carbon dioxide in 160 
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the perfusion medium before and after its passage through the ovary were measured 10 min 161 
after the start of perfusion, and then every 30 min until the end of perfusion using a blood-gas 162 
analysis system (Rapidlap 248 TM, Siemens, Munich, Germany). According to the results of 163 
blood-gas analysis, the supply of carbogen and the flow rate were adjusted to sustain a 164 
physiologic pH (target value, 7.40). Temperature of the perfusion medium was controlled 165 
with a Liebig condenser (GB Kühler Liebig, NSK+H14/23 120mm; UZH Glassblowing 166 
Factory, Zurich, Switzerland) connected to a tempered water circulation (Type SSB4; Grant 167 
Instruments, Cambridge, England). Directly before entering the ovarian artery, temperature of 168 
Tyrode’s solution was measured using a thermometer (WDT, Garbsen, Germany), every 169 
5 min between 0 and 20 min after the start of perfusion, and then every 10 min to the end of 170 
perfusion. According to these measurements, temperature of the water circulation was 171 
adjusted to maintain the Tyrode’s solution between 37 and 38 °C, as reported in similar 172 
studies (Koos et al. 1984, Holmes et al. 1985, Brannstrom & Flaherty 1995). 173 
For perfusion, a volume- and pressure-controlled peristaltic pump (Storz Endomat n. 174 
Hamou; Karl Storz GmbH, Tuttlingen, Germany) was used. Flow was manually determined 175 
with a chronograph and a volumetric flask after 15 and 40 min, and then every 30 min. 176 
Pressure was continuously controlled by means of an instrument for invasive blood pressure 177 
measurement (Cardiocap 5; Datex-Ohmeda GE Healthcare Systems, Little Chalfont, 178 
England), and pressure in the ovarian artery (before entering the ovary) was calculated 179 
concurrent with flow measurements. Pressure was adjusted to achieve a perfusion flow of 180 
approximately 2 mL/min per gram ovarian tissue, as proposed (Stahler & Huch 1971). To 181 
avoid artefacts caused by accumulation of metabolites or hormones, Tyrode’s solution was 182 
not recycled. 183 
 184 
2.4. Study design 185 
 186 
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All ovaries were perfused for 240 min. During the first 60 min (equilibration), no agents 187 
were added. In eight ovaries, 0.5 µg/mL E. coli O55:B5 lipopolysaccharide (LPS O55:B5 188 
lyophilized powder; Sigma Aldrich, St. Louis, MO, USA) was added to the medium for 189 
180 min after equilibration, whereas the other eight ovaries were not treated with LPS 190 
throughout the entire experiment (control). For all ovaries, human chorionic gonadotropin 191 
(hCG, 500 iu; Chorulon 1500®; MSD Animal Health GmbH, Luzern, Switzerland) was added 192 
to the perfusion medium 210 min after the start of perfusion. 193 
 194 
2.5. Glucose, lactate, lactate dehydrogenase, creatine kinase, progesterone, and 195 
prostaglandin F2α 196 
 197 
To ensure that the ovary remained in a physiological state, glucose and lactate 198 
concentrations and activities of lactate dehydrogenase (LDH) and creatine kinase (CK) were 199 
used as markers of hypoxia and cell death (Richter et al. 2000). 200 
Before its passage through the ovary, influent perfusion medium was sampled at 0, 60, 201 
120, and 180 min after the start of perfusion. In addition, effluent perfusion medium was 202 
sampled every 10 min throughout the entire perfusion period. At each time of sampling, three 203 
native aliquots and one aliquot for glucose analysis (containing sodium fluoride as a 204 
glycolysis inhibitor; Vacuette FX Sodium Fluoride / Potassium Oxalate; Greiner bio-one, 205 
Kremsmünster, Austria) were collected and stored at -20 °C (P4) or -80 °C (glucose, lactate, 206 
LDH, CK, PGF2α), respectively. 207 
Glucose concentrations were measured in all samples of influent perfusion medium. In 208 
the effluent perfusion medium, concentrations of glucose and lactate, as well as LDH and CK 209 
activities, were determined in samples collected after 10 min, and then every 30 min until the 210 
end of perfusion. For these measurements, the Cobas Mira Plus analyzer (Roche, Basel, 211 
Switzerland) with kits for glucose (Glucose RTU®; Biomérieux, Lyon, France), lactate 212 
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(Lactate PAP®; Biomérieux), LDH (LDH IFCC®; Axonlab), and CK (Enzyline CK NAC®; 213 
Biomérieux) was used. Analyses of glucose, lactate, LDH, and CK had a range of standard 214 
concentrations of 0.18 to 22.2 mmol/L, 0.04 to 10 mmol/L, 5 to 1200 U/L, and 5 to 1000 U/L, 215 
respectively. Intra- and inter-assay coefficients of variation were ≤0.92 and ≤2.55% for 216 
glucose, ≤1.14 and ≤3.20% for lactate, ≤1.14 and ≤1.41% for LDH, and ≤2.40 and ≤5.56% for 217 
CK, respectively. 218 
Concentrations of P4 were measured in the effluent perfusion medium every 10 min 219 
throughout the duration of perfusion, using a radioimmunoassay (RIA kit IM1188; Beckman 220 
Coulter GmbH, Krefeld, Germany). The range of standard concentrations for this test was 221 
0.05 to 50 ng/mL, intra- and inter-assay coefficients of variation were ≤6.5 and ≤7.2%, 222 
respectively, and 50% of relative binding (ED50) occurred at 1.4 ng/mL. 223 
Concentrations of PGF2α were measured in effluent perfusate at 0, 10, 40, 70, 100, 130, 224 
160, 190, 220, and 240 min of perfusion. A high-sensitivity PGF2α ELISA kit (Enzo Life 225 
Sciences AG, Lausen, Switzerland) was used. For this test, the range of standard 226 
concentrations was 1.95 to 2000 pg/mL, intra- and inter-assay coefficients of variation were 227 
≤7.2 and ≤11.0%, respectively, and ED50 was 81 pg/mL. 228 
 229 
2.6. Corpus luteum biopsy and expression analysis 230 
 231 
A biopsy (approximately 15 x 1 x 1 mm) was obtained from the maximum diameter 232 
(including cells from the periphery and the center) of the CL after 60, 120, 180, and 240 min 233 
of perfusion, using a semi-automatic, high-speed biopsy needle (TEMNO Evolution™; Fa. 234 
Walter, Baruth/Mark, Germany) that was rendered free of RNase (RNase-ExitusPlus™; 235 
AppliChem, Darmstadt, Germany). Tissue samples were immediately placed in a sterile 236 
DNase- and RNase-free cryo tube (Fa. Brand, Wertheim, Germany), frozen in liquid nitrogen 237 
(Dry Shipper Taylor-Wharton CX100; Jensons Scientific, Franklin, USA) and stored 238 
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at -80 °C until expression analysis was done. Immediately after the biopsy was collected, 239 
perforation points on the CL surface were closed with fibrin glue (Histoacryl®; B. Braun 240 
Melsungen AG, Melsungen, Germany). 241 
Luteal mRNA expression was determined for luteinizing hormone / choriogonadotropin 242 
receptor (LHCGR), steroidogenic acute regulatory protein (STAR), 3-beta-hydroxysteroid 243 
dehydrogenase (HSD3B), TLR2 and -4, caspase (CASP) 3, -8 and -9, prostaglandin E- 244 
(PGES/PTGES) and -F (PGFS/AKR1B1) synthases, prostaglandin F receptor (PTGFR/FP), 245 
TNFA, vascular endothelial growth factor A isoform 121 (VEGFA121), fibroblast growth 246 
factor 2 (FGF2), and endothelin 1 (EDN1). Therefore, total RNA from luteal tissue samples 247 
was isolated and reverse-transcribed as described (Ulbrich et al. 2009) and luteal mRNA 248 
expression was determined in a two-step quantitative real-time PCR (qPCR). The qPCR was 249 
performed using the CFX384 Real-Time PCR Detection System (Bio-Rad, Munich, 250 
Germany) and the SsoFast EvaGreen Supermix (Bio-Rad). The qPCR was performed in a 251 
reaction volume of 10 µL, consisting of 5 µL EvaGreen Mix, 0.4 µL of each primer (10 µM), 252 
0.07 µL VisiBlue (TATAA Biocenter, Göteborg, Sweden), 3.13 µL water, and 1 µL cDNA. 253 
Primers used to amplify specific fragments referring to selected regulated genes are shown 254 
(Table 1). Annealing temperature (AT) and melting points (MP) are outlined. The cycle 255 
number (Cq) required to achieve a definite SYBR Green fluorescence signal was calculated by 256 
the regression method (Bio-Rad CFX Manager 3.1). The Cq was inversely correlated to the 257 
logarithm of the initial template concentration. The Cq determined for the target genes were 258 
normalized against the geometrical mean of five reference genes (YWHAZ, H3F3A, 259 
CNOT11, SUZ12, and TBP; ∆Cq). To avoid negative digits while allowing estimation of a 260 
relative comparison between two genes, data were presented as means ± SEM added to the 261 
arbitrary value 20 (∆Cq). Thus, a high ∆Cq proportionally resembled high transcript 262 
abundance (Livak & Schmittgen 2001). 263 
 264 
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2.7. Postprocessing of ovaries 265 
 266 
After the 240 min study period, ovaries with mesovarium were weighed again to 267 
estimate perfusion-induced edema. Subsequently, ovaries were perfused with stained (Patent 268 
blue; Sigma-Aldrich) perfusion medium and dissected to test for smaller leakages and 269 
homogenous staining of the CL. Ovaries with approximately more than one quarter of the 270 
perfusion medium leaking from the ovarian artery before reaching the ovary, and/or with 271 
poorly or non-homogenously stained CL were retrospectively excluded from the study. 272 
Between each perfusion of an ovary, all glassware and tubing that were in contact with the 273 
perfusion medium were cleaned and steam sterilized. 274 
 275 
2.8. Statistical analyses 276 
 277 
Data from only 11 ovaries were used; five ovaries (two from the control and three from 278 
the LPS group) with leakages of the ovarian artery and non-homogenously perfused CL 279 
(determined with Patent blue) were excluded. In excluded ovaries, the pressure in the ovarian 280 
arteries decreased less (P = 0.03) during equilibration than in ovaries that were retained in the 281 
study (22.8 ± 10.3 vs 44.8 ± 4.2 mmHg), indicating higher resistance, probably due to 282 
intravascular coagulation. Consistently, mean P4 concentrations during the complete perfusion 283 
time were lower (P < 0.0001) in excluded (68.0 ± 6.4 ng/mL) than included ovaries (252.9 ± 284 
23.5 ng/mL). 285 
For included ovaries, the average interval between death of the cow and start of isolated 286 
perfusion was 79.1 ± 3.2 min (mean ± SEM; range, 65 to 90 min), with no difference between 287 
ovaries of the control (77.5 ± 4.6 min) and LPS groups (81.0 ± 4.6 min). Furthermore, the 288 
ultrasonographically measured diameter of the CL was similar in control ovaries (27.8 ± 289 
1.4 mm) and ovaries treated with LPS (27.5 ± 0.7 mm). Mean diameters and calculated cross-290 
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sectional areas of the CL ranged from 25.5 to 33 mm and 5.11 to 8.55 cm2, respectively, with 291 
the exception of only one CL with a diameter and area of 22.5 mm and 3.98 cm2, respectively 292 
(for the latter CL, P4 concentration in a blood sample collected immediately before slaughter 293 
was 7.2 ng/mL). Based on cross-sectional areas (n=10) or plasma P4 concentration (n=1), CL 294 
were designated as mid-cycle (Days 8 to 16; Day 1 = ovulation) according to Herzog et al. 295 
(2010). 296 
During equilibration (0 to 60 min after start of perfusion), pressure in the ovarian artery 297 
decreased by similar values in the control (42.1 ± 5.7 mmHg) and the LPS group (47.9 ± 298 
6.6 mmHg), with no changes in arterial pressure during the treatment period (60 to 240 min 299 
after start of perfusion). The mean temperature and flow of the perfusion medium for all 300 
ovaries was 37.9 ± 0.1 °C (37.5 to 38.3 °C) and 37.7 ± 1.4 mL/min (29.3 to 44.5 mL/min), 301 
respectively. During the treatment period, there were no differences between control and LPS 302 
groups for temperature (38.2 ± 0.1 vs 38.2 ± 0.1 °C) or flow (38.0 ± 2.8 vs 36.5 ± 303 
1.3 mL/min) of the perfusion medium. 304 
In five cows of each group, the vascular pedicle started to contract frequently after a 305 
similar duration of perfusion (11.0 ± 1.0 min and 12.0 ± 2.6 min in the control and LPS 306 
groups, respectively). Total interval of frequent contractions did not differ between cows of 307 
the control (227.0 ± 2.0 min) and the LPS group (228.0 ± 2.6 min). During the last hour of 308 
perfusion, an intensification of contractions (not quantified) occurred in four ovaries of the 309 
LPS group, whereas contractions became less intense in the control group. The increase in 310 
weight of ovaries with vascular pedicle (due to edema in the mesovarium) did not differ 311 
between the control (30.3 ± 7.2 g) and the LPS group (47.1 ± 8.6 g). 312 
Analysis of CK had a lower detection limit of 5 U/L. For measurements below this 313 
limit, 4 U/L was used as an arbitrary value to facilitate statistical analysis. 314 
Distribution of the data was assessed visually for normality (PROC CHART) and by 315 
means of the Shapiro-Wilk-test (PROC UNIVARIATE). Because data were normally 316 
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distributed, independent (between groups; PROC TTEST) and dependent (within groups; 317 
PROC UNIVARIATE) pairwise comparisons were done using a Student’s t-test, in due 318 
consideration of repeated measures. All statistical analyses were done with the Statistical 319 
Analysis System V9.1 (SAS Institute Inc., Cary, NC, USA), and P ≤ 0.05 was considered 320 
significant.321 
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3. Results 322 
 323 
Mean glucose consumption during the perfusion time did not differ between control 324 
ovaries (mean ± SEM; 0.2 ± 0.03 mmol/L) and ovaries treated with LPS (0.2 ± 0.02 mmol/L). 325 
On a per-time basis, glucose consumption was higher (P = 0.03) in the LPS group compared 326 
to the control group at 180 min after the start of LPS challenge (Fig. 4A). Average lactate 327 
production during the perfusion period was not different between ovaries of the control (0.2 ± 328 
0.04 mmol/L) and the LPS groups (0.2 ± 0.02 mmol/L), but on a per-time basis, lactate 329 
concentrations were increased 70 (P = 0.01) and 100 min (P = 0.03) after the start of treatment 330 
in ovaries of the LPS group compared to control ovaries (Fig. 4B). Mean enzyme activities of 331 
LDH and CK decreased (P < 0.05) during the equilibration time to nearly half of initial 332 
values, but thereafter remained relatively constant. For control and LPS ovaries, mean 333 
activities of LDH (12.3 ± 6.1 vs 7.3 ± 2.6 U/L, respectively) and CK (11.7 ± 2.3 vs 9.8 ± 334 
1.1 U/L) were similar throughout the entire perfusion period. Furthermore, there was no 335 
difference in LDH and CK activities between these two groups on a per-time basis (Fig. 4C, 336 
D). In summary, parameters that characterized perfusion requirements (glucose consumption, 337 
lactate production, and activities of LDH and CK) were in a physiologic range at the start of 338 
the treatment period in both groups. 339 
Progesterone concentrations in the effluent perfusate remained constant during the first 340 
150 min of LPS treatment (mean ± SEM; 223.2 ± 41.3 ng/mL) and were similar to those of 341 
control ovaries (268.5 ± 35.0 ng/mL). However, after hCG challenge (150 min after the start 342 
of LPS treatment), P4 concentrations increased in control, but not in LPS ovaries, and reached 343 
higher (P = 0.04) concentrations in control (402.4 ± 39.9 ng/mL) compared to LPS ovaries 344 
(241.9 ± 56.8 ng/mL) 30 min later (Fig. 5). 345 
Mean concentrations of PGF2α did not differ between the control (22.8 ± 6.9 pg/mL) 346 
and LPS groups (53.0 ± 18.5 pg/mL) throughout the entire treatment period. Furthermore, 347 
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there was no significant difference in PGF2α concentrations between ovaries treated with LPS 348 
and control ovaries on a per-day basis (Fig. 6) but PGF2α concentrations tended (P = 0.10) to 349 
be higher in LPS compared to control ovaries at 70 min after LPS challenge. After hCG 350 
challenge, PGF2α concentrations did not change within LPS and control ovaries.  351 
Changes in mRNA expression of all investigated parameters are shown (Figure 7). 352 
Luteal mRNA expression of steroidogenic factors STAR and HSD3B did not differ between 353 
the control and the LPS group for any time of analysis (Fig. 7A). Furthermore, expression of 354 
LHCGR did not differ between groups at any time (Fig. 7A). However, mRNA expression of 355 
TNFA in the LPS group was higher at 60 (P = 0.0002) and 120 min (P = 0.004) after the start 356 
of treatment compared to the control group (Fig. 7B). Furthermore, luteal expression of TLR2 357 
was higher (P = 0.03) 180 min after the start of treatment in the LPS compared to the control 358 
group, whereas expression of TLR4 did not differ between groups at any time (Fig. 7B). 359 
Analysis of apoptotic factors revealed higher mRNA expression in the LPS group for 360 
CASP3 at 60 (P = 0.02), 120 (P < 0.0001) and 180 min after start of treatment (P < 0.0001; 361 
Fig. 7C). Higher expressions were also observed for CASP8 at 60 (P = 0.05) and 180 min 362 
(P = 0.01) after the start of LPS treatment compared to control ovaries, although CASP9 did 363 
not differ between groups at any time (Fig. 7C). 364 
Whereas mRNA expressions of PGES and PGFS were higher in the LPS group at 120 365 
(P = 0.008; only PGES) and 180 min (P = 0.03 and P = 0.05, respectively) compared to the 366 
control group, expression of PTGFR did not differ between groups during the treatment 367 
period (Fig. 7D). Luteal mRNA expression of angiogenic factor VEGFA121 was higher 368 
(P = 0.05) at 60 min after the start of treatment in the LPS compared to the control group 369 
(Fig. 7E). In contrast, expressions of FGF2 and EDN1 did not differ at any time between the 370 
control and the LPS group (Fig. 7E). 371 
372 
Page 16 of 42
17 
 
4. Discussion 373 
 374 
In the present study, great efforts were made to maintain energy metabolism and 375 
viability of the ovaries similar to a physiological situation in vivo during the 3-h interval after 376 
equilibration. Therefore, the duration of ischemia was kept to a minimum, with an effort to 377 
maintain physiologic pressure in the ovarian artery, glucose consumption, lactate production, 378 
and LDH and CK activities to control vascular resistance (arterial pressure), oxygenation 379 
(glucose, lactate) and cytolytic tissue processes (LDH, CK), as suggested (Stahler & Huch 380 
1971, Richter et al. 2000). Arterial perfusion pressure decreased markedly during 381 
equilibration but remained stable thereafter, indicating normalization of vascular resistance 382 
after re-perfusion. Furthermore, comparable metabolic activities in ovaries of the control and 383 
the LPS group were inferred, based on similar glucose consumption between groups. Lactate 384 
concentrations decreased directly after the start of perfusion in both groups. High lactate 385 
concentrations before perfusion were attributed to initial hypoxia (Ahren et al. 1972); 386 
therefore, re-perfusion with oxygenated medium decreased lactate production to physiologic 387 
values before the start of the treatment period. High concentrations of LDH and CK, as 388 
indicators of cell death during ischemia, decreased to a low and constant level within the 389 
equilibration period, consistent with a study on isolated perfused human uteri (Richter et al. 390 
2000). In conclusion, there was good evidence that after equilibration, the general conditions 391 
were relatively physiologic, and therefore results obtained during the treatment period were 392 
reliable. 393 
Increased lactate concentrations 70 min after the start of LPS challenge and the higher 394 
values in the LPS compared to the control group indicated increased metabolic activity, 395 
attributed to LPS-induced activation of immune defense mechanisms. Higher glucose uptake 396 
in the LPS group at the end of the perfusion period, which also indicated increased metabolic 397 
activity, was probably due to intensified contractions of the vascular pedicle in the LPS group 398 
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compared to the control group. Consistently, rhythmic contractions (2- to 3-min intervals) of 399 
the vascular pedicle and the hilus area of the ovary were clearly visible in isolated perfused 400 
sheep ovaries and the vascular pedicle was responsible for a non-negligible portion of glucose 401 
uptake (Janson et al. 1978). 402 
Luteal mRNA expression of TNFA was significantly higher in ovaries treated with LPS 403 
than in control ovaries 60 and 120 min after the start of treatment. Consistently, LPS induces 404 
TNFA production and the activated cytokine cascade (involving TNFA) mediates the acute 405 
phase response to endotoxins (Kushibiki 2011). Functional TNF receptors were present in 406 
steroidogenic and endothelial cells of bovine CL (Okuda et al. 1999, Okuda & Sakumoto 407 
2003). Therefore, the ability of TNFA to modulate the lifespan of the bovine CL may largely 408 
depend on the direct action on CL cells (Skarzynski et al. 2007). In cultured steroidogenic 409 
luteal cells, TNFA inhibited gonadotropin-stimulated secretion (Benyo & Pate 1992), 410 
consistent with failure of LPS-treated ovaries to increase P4 concentrations after challenge 411 
with hCG in the present study. Furthermore, TNFA acting via TNF receptor-1 induced 412 
apoptotic death of steroidogenic and endothelial cells of the bovine CL through inactivation of 413 
the anti-apoptotic protein Bcl-2 and by stimulating expression and activity of CASP3 414 
(Skarzynski et al. 2005). Consistently, CASP3 mRNA expression was increased 60, 120 and 415 
180 min after the start of treatment in the LPS group compared to the control group. 416 
Furthermore, mRNA expression of CASP8 was increased 60 and 180 min after the start of 417 
LPS treatment, whereas CASP9 mRNA expression did not differ between LPS and control 418 
groups, suggesting the importance of the extrinsic (death receptor mediated) pathway of 419 
apoptosis. 420 
Progesterone concentrations in the effluent perfusate did not significantly change during 421 
the first 150 min after treatment with LPS (similar values in the two groups). In a previous 422 
study on isolated perfused bovine ovaries (Sturm & Stahler 1971), P4 concentrations in the 423 
perfusate of untreated ovaries were 175 to 291 ng/mL, indicating adequate luteal release of P4 424 
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in the present study. Previously, measurements of P4 content in luteal tissue before and after 425 
in vitro perfusion indicated that changes in P4 concentrations of the effluent perfusate resulted 426 
from differences in P4 synthesis and release and not from leakage of P4 already present in the 427 
CL prior to perfusion (Dharmarajan et al. 1988). Furthermore, concentrations of P4 in the 428 
perfusate corresponded well with those synthesized in the tissue of CL from isolated perfused 429 
ovaries (Brannstrom & Flaherty 1995), which were regarded as evidence of adequate 430 
secretory capacity. However, our results were not consistent with an initial increase (within 431 
30 min) and subsequent decline (until 9 h) of P4 concentrations in an in vivo study involving 432 
cows given LPS by intravenous treatment (Herzog et al. 2012). Notwithstanding, our results 433 
supported the assertion that the initial increase in P4 after treatment with LPS in vivo might be 434 
of adrenal origin due to activation of a neuroendocrine stress axis (Kujjo et al. 1995, Herzog 435 
et al. 2012). 436 
Since LH or hCG significantly increase P4 production in bovine midcycle CL (Koos et 437 
al. 1984, Litch & Condon 1988), an hCG challenge was used in the present study to assess 438 
secretory capacity of the CL during isolated perfusion. It was noteworthy that P4 increased 439 
significantly 30 min after application of hCG in the control, but not in the LPS group. In 440 
cattle, LH binds to its specific receptor LHCGR and ultimately increases synthesis of STAR 441 
and activity of cytochrome P450scc and HSD3B, followed by an increase in P4 secretion 442 
(Rekawiecki et al. 2005). However, in control ovaries in the present study, mRNA 443 
expressions of LHCGR, STAR and HSD3B were not increased 30 min after hCG challenge, 444 
although P4 concentrations were already higher at that time. Consistently, concentrations of 445 
mRNA for STAR, and HSD3B (measured at 3-h intervals) were not increased until 6 h after 446 
luteal cell stimulation with LH (Rekawiecki et al. 2005). Furthermore, LH responsiveness 447 
seemed to be more dependent on the extent of desensitization of luteal cells to LH (e.g., by 448 
extensive clustering and internalization of the receptor complex) than on the number of LH 449 
receptors, as during functional luteolysis, luteal cells apparently became desensitized to LH, 450 
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despite maintenance of LHCGR (Amsterdam et al. 2002). However, we inferred that the 451 
absence of an increase in P4 concentrations after LPS challenge was due to inhibited luteal 452 
release rather than synthesis of P4. Release of P4 from the ovine CL was regulated by calcium-453 
dependent depolarization of the luteal cell membrane after stimulation with LH in vitro 454 
(Higuchi et al. 1976). 455 
Moreover, luteal PGF2α concentrations in LPS-treated ovaries did not increase 456 
significantly, although there was a trend towards significance. The release of PGF2α from the 457 
uterus is essential to suppress P4 concentrations during luteolysis at the end of the estrous 458 
cycle (McCracken et al. 1981). Whereas uterine PGF2α has been clearly linked to luteolysis 459 
(Schams & Berisha 2004), it is a debatable point whether luteal PGF2α had a luteolytic effect 460 
in the present study. However, changes in luteal mRNA expressions in ovaries of the LPS 461 
group do not resemble changes observed after exogenous PGF2α treatment in cows, including 462 
decreased mRNA expressions of PTGFR, steroidogenic (STAR, HSD3B) and angiogenic 463 
factors (VEGF, FGF2), and increased vasoactive factor EDN1 mRNA expression (Shirasuna 464 
et al. 2010). In the present study, there were no significant differences in these parameters 465 
between control and LPS ovaries, except for a temporary increase in VEGFA121, indicating a 466 
non-specific response to LPS challenge. Therefore, we inferred that luteal PGF2α was 467 
probably not primarily responsible for LPS-induced changes in the present study. 468 
Tumor necrosis factor alpha is a potent stimulator of luteal synthesis of prostaglandins 469 
(including luteolytic PGF2α and luteotropic PGE2), consistent with increased mRNA 470 
expressions of PGES at 120 and 180 min and PGFS at 180 min after the start of LPS 471 
treatment compared to control ovaries, similar to a previous report (Okuda et al. 1999). In 472 
bovine endometrial cells, PGE2 and PGF2α production were elevated after LPS challenge 473 
(Herath et al. 2006), in association with extended luteal phases and premature regression of 474 
the CL, respectively (Opsomer et al. 2000). The predominant effect (luteotropic or luteolytic) 475 
was dependent on PGE2 to PGF2α ratio (Herath et al. 2006) and luteal phase (Shirasuna et al. 476 
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2010), with PGE2 primarily controlling the early and PGF2α the mid- and late luteal phases, 477 
respectively. In the present study using mid-luteal CL, increased mRNA expression of PGFS 478 
in the LPS group compared to the control group might have contributed to lower P4 479 
concentrations after hCG challenge in LPS-treated ovaries. Bovine PGFS mRNA encodes for 480 
20α-hydroxysteroid dehydrogenase (20α-HSD; Madore et al. 2003, Schuler et al. 2006) that is 481 
responsible for P4 catabolism within the CL (Naidansuren et al. 2011), and therefore might 482 
decrease P4 in the effluent perfusate. Furthermore, luteal cells that express 20α-HSD not only 483 
lose their capacity to secrete P4, but also facilitate expression of the death receptor Fas on 484 
their surface (Stocco et al. 2007), thereby enhancing apoptosis. 485 
The main receptor for recognition of LPS is TLR4 (Akira 2003), whereas TLR2 486 
predominantly recognizes peptidoglycans and lipoteichoic acid (Takeuchi et al. 1999). 487 
Expression of both receptors was reported in bovine ovaries (Vahanan et al. 2008). 488 
Interestingly, mRNA expression of TLR4 did not differ significantly between control and 489 
LPS-treated ovaries in the present study, whereas expression of TLR2 was higher in the LPS 490 
than in the control group 180 min after the start of treatment. Binding of the respective 491 
pathogens to TLR2 and -4 initiated a signaling cascade that resulted in release of TNFA and 492 
other cytokines (Kannaki et al. 2011). Since TNFA increased TLR2 mRNA expression in 493 
various murine (Matsumura et al. 2000) and human (Davanian et al. 2012) tissues, an 494 
involvement of TNFA in higher mRNA abundance of TLR2 after LPS challenge may have 495 
occurred in the present study. 496 
In conclusion, treatment with LPS inhibited hCG-induced P4 secretion in the bovine CL. 497 
The reduced P4 secretion seemed to be predominantly caused by an increase in LPS-induced 498 
apoptosis, but not by decreased steroidogenic factors. Regardless, an impact of luteal PGF2α 499 
could not be excluded. 500 
501 
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Figure legends 1 
 2 
Fig. 1. Mesovarium stretched between the left ovary (A) and the left uterine horn (B) to 3 
display the ovarian artery (1) with its ramus uterinus (2) and ramus tubarius (3). 4 
Catheterization was performed at the marked position (       ) proximally from the location 5 
where the ramus uterinus branched from the ovarian artery. 6 
 7 
Fig. 2. Position of the ovary fixed at its extremitates tubaria and uterina on a bipod with the 8 
vascular pedicle (including the ovarian artery and vein) hanging downwards. The yellow color 9 
of the corpus luteum confirmed adequate preparation after flushing with heparinized Tyrode’s 10 
solution. 11 
 12 
Fig. 3. Schematic view of equipment used for isolated perfusion of bovine ovaries. 13 
 14 
Fig. 4. Changes (means ± SEM) in glucose consumption (A), lactate concentration (B), and 15 
activities of lactate dehydrogenase (C) and creatine kinase (D) of control ovaries (     ; n=6) 16 
and ovaries treated with LPS (     ; n=5) during equilibration and treatment times of perfusion. 17 
* Difference between the two groups (P ≤ 0.05) at times indicated. 18 
 19 
Fig. 5. Changes (means ± SEM) in progesterone concentrations of the effluent perfusate from 20 
control ovaries (     ; n=6) and ovaries treated with LPS (     ; n=5) during the treatment period 21 
of perfusion. 22 
       Treatment with 500 iu hCG. 23 
*Difference between the two groups (P ≤ 0.05) at times indicated. 24 
 25 
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Fig. 6. Changes (means ± SEM) in prostaglandin F2α concentrations of effluent perfusate from 26 
control ovaries (     ; n=6) and ovaries treated with LPS (     ; n=5) during the treatment period 27 
of perfusion. 28 
       Treatment with 500 iu hCG. 29 
 30 
Fig. 7. Changes (means ± SEM) in luteal mRNA expression of steroidogenic acute regulatory 31 
protein (STAR), 3-beta-hydroxysteroid dehydrogenase (HSD3B), luteinizing hormone / 32 
choriogonadotropin receptor (LHCGR), caspase (CASP) 3, CASP8, CASP9, tumor necrosis 33 
factor alpha (TNFA), toll-like receptor (TLR) 2, TLR4, prostaglandin E synthase (PGES), 34 
PGFS, prostaglandin F receptor (PTGFR), vascular endothelial growth factor A isoform 121 35 
(VEGFA121), fibroblast growth factor 2 (FGF2), and endothelin 1 (EDN1) of control ovaries 36 
(white columns; n=6) and ovaries treated with LPS (black columns; n=5) during the treatment 37 
period of perfusion. 38 
* Difference between groups (P ≤ 0.05) at times indicated. 39 
 40 
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Table 1. Sequences and accession numbers of PCR primers for assayed genes from bovine corpus luteum cells, and length, annealing (AT) and 1 
melting point (MP) temperatures of PCR products. 2 
 3 
Gene Gene symbol Reference Forward primer Reverse primer 
PCR  
product 
AT MP 
  [acc. no.] [5’-…-3’] [5’-…-3’] [bp] [°C] [°C] 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
YWHAZ NM_174814.2 AGGCTGAGCGATATGATGAC GACCCTCCAAGATGACCTAC 141 60 81 
histone H3F3A NM_001014389.2 ACTGGCTACAAAAGCCGCTC ACTTGCCTCCTGCAAAGCAC 233 60 85 
CCR4-NOT transcription complex, subunit 11 CNOT11 XM_582695.6 TCAGTGGACCAAAGCCACCTA CTCCACACCGGTGCTGTTCT 170 60 87 
suppressor of zeste 12 homolog (Drosophila) SUZ12 NM_001205587.1 CATCCAAAAGGTGCTAGGATAGATG TGGGCCTGCACACAAGAATG 160 60 82 
TATA box binding protein TBP NM_001075742.1 CAGAGAGCTCCGGGATCGT CACCATCTTCCCAGAACTGAATAT 194 60 83 
luteinizing hormone / choriogonadotropin receptor LHCGR NM_174381.1 GGAAATGGATTTGAAGAAATACAA GTGCTTTCACATTGTTTGGAAAAG 376 60 85 
steroidogenic acute regulatory protein STAR NM_174189.2 GGATTAACCAGGTTCGGCG CTCTCCTTCTTCCAGCCCTC 157 60 89 
3-beta-hydroxysteroid dehydrogenase HSD3B NM_174343.3 TACCCAGCTGCTGTTGGA ATGCCGTTGTTATTCAAGGC 322 60 87 
toll-like receptor 2 TLR2 NM_174197.2 CCATGTGGAGAGGGTGTT GGGGACACAAAACAGCACTT 138 60 81 
toll-like receptor 4 TLR4 NM_174198.6 GACCCTTGCGTACAGGTTGT GGTCCAGCATCTTGGTTGAT 103 60 80 
caspase 3 CASP3 NM_001077840.1 AACCTCCGTGGATTCAAAATC TTCAGGRTAATCCATTTTGTAAC1 114 60 80 
caspase 8 CASP8 NM_001045970.2 TGTCACAATCGCTTCCAGAG GAAGTTCAGGCACCTGCTTC 183 60 83 
caspase 9 CASP9 NM_001205504.1 GTGGTGGAGAGCAGAAAGAC AAACTAGACACGGCATCTGG 145 60 86 
prostaglandin E synthase PGES (PTGES) NM_174443.2 TCCTGGTCTTCTTCCTGGG CCCAGACAATCTGCAGGG 132 60 88 
prostaglandin F synthase PGFS (AKR1B1) NM_001012519.1 ATACAAGCCGGCGGTTAAC TGTCTGCAATCGCTTTGATC 188 60 86 
prostaglandin F receptor PTGFR (FP) NM_181025.3 AGCCTTGCCATTGCTATCC TAGTTCCATTGATGAGGTGCC 127 60 80 
Page 34 of 42
2 
 
tumor necrosis factor alpha TNFA NM_173966.3 CCACGTTGTAGCCGACATC ACCACCAGCTGGTTGTCTTC 108 60 86 
vascular endothelial growth factor A isoform 121 VEGFA121 NM_174216 CCGTCCCATTGAGACCCTG CGGCTTGTCACAATTTTTCTTGTC 280 60 87 
fibroblast growth factor 2 (basic) FGF2 NM_174056.3 GAACGGGGGCTTCTTCCT CCCAGTTCGTTTCAGTGCC 288 60 81 
endothelin 1 EDN1 NM_181010.2 CTCTTCCCTGATGGATAAAGAGTG GAACAACGTGCTCTGGAGTG 80 60 79 
1 degenerate multispecies primer, R = A or G 4 
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incubator: 
   T:     37.5 - 38.5°C 
   RH:  75 - 85%  
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E) Angiogenic and vasoactive factors 
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